40
Participants
Start Date
March 31, 2014
Primary Completion Date
December 31, 2019
Study Completion Date
December 31, 2019
Ecopipam
Ecopipam is a selective antagonist of the dopamine D1 receptor family.
Weill Cornell Medical School, New York
North Shore-Long Island Jewish Hosptial, Manhasset
Emory University School Of Medicine, Atlanta
University of South Florida/Rothman Center for Neuropsychiatry, St. Petersburg
Cincinnati Children's Hospital, Cincinnati
University of Chicago Medical School, Chicago
Washington University School of Medicine, St Louis
Children's Mercy Kansas City, Kansas City
Baylor College of Medicine, Houston
UCLA, Los Angeles
Overlook Hospital, Summit
Lead Sponsor
Psyadon Pharma
INDUSTRY
Emalex Biosciences Inc.
INDUSTRY